Kyowa Kirin’s Strategic Partner Sandoz KK Receives Nod for Rituximab Biosimilar

Tokyo-based pharmaceutical company Kyowa Kirin has made a significant announcement regarding the approval of its Rituximab biosimilar for the treatment of lupus nephritis. The approval, granted to Kyowa Kirin’s strategic partner Sandoz KK, paves the way for patients with inadequate responses to conventional therapy to access this innovative treatment.

Related article: Innovent Biologics Bags Chinese Approval for Fourth Monoclonal Antibody

Rituximab Biosimilar’s Mechanism of Action

Kyowa Kirin’s Rituximab biosimilar is a genetic recombinant of the rituximab antibody, offering a mechanism of action that includes antibody-dependent cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and B-cell depletion through apoptosis. This multifaceted approach enhances its effectiveness in treating lupus nephritis, a condition that requires tailored therapeutic solutions.

Under the agreement established on January 26, 2016, with Sandoz, Kyowa Kirin assumes the responsibility for sales and marketing of the Rituximab biosimilar in Japan. This collaboration exemplifies the pharmaceutical industry’s commitment to ensuring that groundbreaking treatments like this biosimilar reach the patients who need them.

Kyowa Kirin’s Ongoing Commitment to Health and Well-being

Kyowa Kirin’s dedication to improving the health and well-being of people worldwide remains central to its mission. The company’s global efforts revolve around creating new value through advancements in life sciences and cutting-edge technologies. This recent approval is a testament to Kyowa Kirin’s commitment to pushing the boundaries of medical innovation, ultimately benefiting patients and the broader healthcare community.

Author

Sinead Huang